Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.

Jun YinWenya YinLinlin ZhengYimin LiCheng LuoShuo ZhangLei DuanHang ZhouKai ChengJinyi LangKe Xu

Published in: Clinical Medicine Insights. Oncology (2023)

Anlotinib had a low incidence of AEs and good safety in the treatment of recurrent high-grade glioma. Moreover, it showed good short-term effectiveness and significantly prolonged the PFS of patients, which may become a promising therapeutic option for recurrent high-grade glioma and lay a foundation for further clinical studies.

Keyphrases

high grade
low grade
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
systematic review
combination therapy
risk factors
prognostic factors
clinical trial
patient reported outcomes
study protocol